Synopsis
Recognise smoking-associated periductal infection, drain abscesses, prescribe anaerobic and staphylococcal coverage from current local guidance, and plan definitive fistula care after acute inflammation settles.
- Non-lactational periareolar infection arises around major subareolar ducts and differs from lactational mastitis in microbial mix, recurrence pattern and association with smoking.
- Squamous metaplasia and keratin plugging can rupture a duct, producing painful subareolar inflammation, abscess and eventually a mammary duct fistula at the areolar edge.
- Assess smoking, diabetes, immune compromise, prior abscesses and procedures, then use ultrasound to identify fluid and distinguish a collection from a persistent solid lesion.
Key red flags
A persistent retroareolar mass, fixed inversion or peau d’orange after infection treatment requires urgent cancer assessment and representative tissue diagnosis.
Investigation priorities
Map dilated ducts, inflammatory tissue, abscess and any separate solid component.
Management branches
A non-lactating smoker has three days of periareolar pain and erythema with a deep tender thickening but stable observations.
- Assess severity, diabetes, allergy, previous organisms and any nipple piercing, then examine for fluctuation, fistula and cancer warning signs.
- Arrange targeted ultrasound promptly because a deep central collection may not fluctuate and would require drainage.
Key medicines
Co-amoxiclavNHS Dumfries & Galloway uses co-amoxiclav 500/125 mg orally three times daily for 10–14 days for central periductal infection. This standard adult tablet schedule assumes weight at least 40 kg, CrCl above 30 mL/min and no contraindication; take the selected Sandoz tablets with a meal. Review clinical response and do not extend beyond 14 days without reassessment.Contraindicated with hypersensitivity to the product or penicillins, a previous severe immediate reaction to another beta-lactam, or prior amoxicillin/clavulanate-associated jaundice or hepatic impairment. Serious delayed penicillin reactions also preclude routine reuse. At CrCl 10–30 mL/min use 500/125 mg twice daily; below 10 use it once daily, with a separately prescribed dialysis schedule when applicable. Existing hepatic impairment needs cautious dosing and regular liver monitoring. Check warfarin/INR on addition or withdrawal, methotrexate toxicity and mycophenolate clinical monitoring; probenecid coadministration is not recommended. Stop and assess significant allergic or severe diarrhoeal reactions. Culture and severity guide treatment; this outpatient example does not cover sepsis or presumed resistant infection.